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Abstract
Background: Analyses of Japanese A-bomb survivors' cancer mortality risks are used to establish
recommended annual dose limits, currently set at 1 mSv (public) and 20 mSv (occupational). Do
radiation doses below 20 mSv have significant impact on cancer mortality in Japanese A-bomb
survivors, and is the dose-response linear?
Methods: I analyse stomach, liver, lung, colon, uterus, and all-solid cancer mortality in the 0 – 20
mSv colon dose subcohort of the 1950–90 (grouped) mortality cohort, by Poisson regression using
a time-lagged colon dose to detect latency, while controlling for gender, attained age, and age-at-
exposure. I compare linear and non-linear models, including one adapted from the cellular
bystander effect for α particles.
Results: With a lagged linear model, Excess Relative Risk (ERR) for the liver and all-solid cancers
is significantly positive and several orders of magnitude above extrapolations from the Life Span
Study Report 12 analysis of the full cohort. Non-linear models are strongly superior to the linear
model for the stomach (latency 11.89 years), liver (36.90), lung (13.60) and all-solid (43.86) in fitting
the 0 – 20 mSv data and show significant positive ERR at 0.25 mSv and 10 mSv lagged dose. The
slope of the dose-response near zero is several orders of magnitude above the slope at high doses.
Conclusion: The standard linear model applied to the full 1950–90 cohort greatly underestimates
the risks at low doses, which are significant when the 0 – 20 mSv subcohort is modelled with
latency. Non-linear models give a much better fit and are compatible with a bystander effect.
Background
Studies of the Japanese A-bomb survivors cohort have
been the key source of radiation risk estimates used to
establish environmental and occupational protection
standards [1,2] despite the differences between instanta-
neous exposure in war to gamma and neutron irradiation,
and chronic low dose occupational or public exposure in
general or to alpha particles. There is an unresolved
debate [3] on whether Excess Relative Risk (ERR) increases
linearly with dose across a very large range of exposures
including the low dose range.
Currently the International Commission on Radiological
Protection (ICRP) recommends an annual occupational
dose limit of 20 mSv (whole body dose), and many
researchers believe that doses below this level have little
or no impact on human health. The ICRP risk estimates
are strongly based on analyses of the Japanese data for the
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full dose range assuming a linear dose response. On the
other hand in the Life Span Study Report 12 (henceforth
LSS12) Pierce et al. [4] adopted a linear ERR model for the
Japanese data but found some evidence of a non-linear
convex dose-response at lower doses for the category of
all-solid cancers combined.
Around one third of the data in the 1950–90 mortality
cohort analysed in LSS12 concerns persons who received
0 – 20 mSv instantaneous exposure in 1945. There is no
reason to assume any particular relation between dose
response in this region and across the entire follow-up.
Instead, the low dose data may be analysed in its own
right with or without assuming a linear dose response.
In experiments at cell level, low dose radiation induces
significant and non-linear effects on micronuclei, chro-
mosome rearrangements and instability, point mutations,
and changes in cell cycle protein levels. Studies reviewed
by Mothersill and Seymour [5] show low doses have large
effects on cells whose nuclei, or even the affected cells
themselves, need not be directly traversed by radiation
(bystander effects). Some studies find responses rising
rapidly with dose and then reaching a plateau. Whilst
these early non-linear cellular events may be critical for
tumour formation, the human body's defences may also
greatly alter the initial dose response or dilute its signifi-
cance, if the analysed outcome is a cancerous tumour
emerging decades later and eventually identified as cause
of death.
I analyse the five leading cancer sites (stomach, liver, lung,
colon, and uterus) and the grouped category of all-solid
cancers in the 0 – 20 mSv portion of the 1950 – 90 Japa-
nese mortality cohort. Follow-up began 5 years after expo-
sure but rather than assume this lag to be optimal, latency
is estimated for individual cancers by fitting models
which include a variable latent period. I test linearity in
the dose response by modelling with two nested non-lin-
ear models, each of which contains the linear model.
Methods
Life Span Study mortality cohort data (1950–1990) were
obtained from the Radiation Effects Research Foundation
[6] via the Comprehensive Epidemiologic Data Resource
[7]. The file r12canc.dat includes anonymous information
on a cohort of 86 572 survivors, presented as 16 612
grouped data cells cross-tabulated by city, sex, total
shielded kerma, exposure age and attained age categories,
and dose category. Cell data includes a weighted adjusted
colon dose, representing an average of individual instan-
taneous ("flash") doses weighted by person-years within
the cell (and assuming neutron Relative Biological Effec-
tiveness RBE = 10). Mean age-at-exposure, mean attained
age, and deaths from specific cancers or grouped cancer
categories are also shown for each cell. Liver cancer (ICD9
155(0,1,2)) includes both deaths attributed to primary
liver cancer, and deaths which were not specified as pri-
mary or secondary liver cancer. Cancer of the uterus refers
to ICD9 180–182, including cervical cancer (ICD9 180).
The data uses the DS86 dosimetry [8], but a limited com-
parison with the current DS02 dosimetry [9-11] is under-
taken.
Subcohorts are defined by restricting weighted adjusted
colon dose as given in the cell data. The 0 – 20 mSv sub-
cohort has 3011 cells comprising 1690391.75 person-
years (p-y) observation. This subcohort consists of exactly
those cells whose individual members received no more
than 20 mSv adjusted colon dose (3009 cells have dose
category 1 or 2, while two other cells each contain a single
person at risk whose adjusted colon dose was 20 mSv).
Other subcohorts defined below lack such simple inter-
pretation.
Specified cancer deaths in the ith cell are assumed to be
Poisson distributed with expected value λiTi where Ti is p-
y observation and λi depends on control variables and a
lagged dose Dφ defined for each cell as weighted adjusted
colon dose (in 10 mSv units) if Time-Since-Exposure ≥ φ
and 0 otherwise. Time-Since-Exposure = mean attained
age – mean age at exposure.
The models below assume
λ = λ0 (1 + ERR)
λ0 = 
where yj are control variables while ERR depends on Dφ
and parameters θk (including φ) but not on control varia-
bles or their parameters.
Gender, log mean attained age, and 14 indicator variables
defined by 0 ≤ age-at-exposure < 5, 5 ≤ age-at-exposure <
10,... and 65 ≤ age-at-exposure < 70 were used as controls.
Indicator variables defined from mean age-at-exposure
(cell data) are identical to those defined from the age-at-
exposure stratification of the dataset. An indicator defined
by 70 ≤ age-at-exposure would be redundant. Log mean
attained age was an adequate alternative to the use of
attained age categories.
Four models were fitted:
Linear ERR = βDφ
Transient ERR = σDφ []  w i t h  τ ≥ 0
e
jjj () αβ +Σ y
e
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Two-phase ERR =βDφ + σDφ []  w i t h  τ ≥ 0
Category ERR = β1(dosecat1) + β2(dosecat2) +
β3(dosecat3)
The usual Linear model is used here with lagged dose. The
Control model (ERR = 0) is nested when β = 0.
The  Transient  model gives an asymptotic linear dose
response at very low doses, decaying to zero at higher
doses if τ > 0. The Linear model is nested when τ = 0, while
σ = 0 nests the Control model.
The Two-phase  model gives an asymptotic linear dose
response at very low doses, and a possibly different
asymptotic linear response at higher doses, with an expo-
nential transition between the two. The Transient model
is nested when β = 0, while σ = 0 (or τ = 0) nests the Linear
model. The Control model is nested when β = σ = 0, or
when τ = 0 and β + σ = 0. ERR ~ βDφ when τ Dφ >> 1, while
ERR ~ (β + σ)Dφ when τ Dφ << 1. The ratio of asymptotic
slopes is R = 1 + σ/β.
Typical dose-response curves for these three models are
shown in Figure 1.
The Category model uses indicator variables defined by
cutpoints 0 < γ1 < γ2
dosecat1 = 1 if 0 < Dφ ≤ γ1 and = 0 otherwise
e
D () −τ φ
Dose response prototypes for linear, transient, and two-phase models Figure 1
Dose response prototypes for linear, transient, and two-phase models. Typical dose response curves for the linear 
model ERR = βD where ERR is Excess Relative Risk and D is a dose variable (arbitrary units), the transient model ERR = σDe(-
τD), and the two-phase model ERR = βD + σDe(-τD). Here β, σ, τ are parameters with τ ≥ 0. The linear model is shown with β 
> 0. Two versions of the transient model are shown, with σ > 0 and with σ < 0. The transient model converges to 0 as dose 
→ ∞. Two versions of the two-phase model are shown, with σ >> β > 0 and -σ >> β > 0; the first version occurs when β > 0 
and σ/β > e2 ~ 7.39. Other possibilities (not shown) lack local maxima and minima, but the two-phase model always converges 
to the linear model as dose → ∞.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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dosecat2 = 1 if γ1 < Dφ ≤ γ2 and = 0 otherwise
dosecat3 = 1 if γ2 < Dφ and = 0 otherwise
The Control model is nested by β1 = β2 = β3 = 0. Dφ = 0 also
defines the baseline. The model is applied here only with
latencies obtained from the two-phase model, and cut-
points γ1 = 0.025 (0.25 mSv), γ2 = 0.05 (0.5 mSv) which
assign roughly equal p-y to dosecat1, dosecat2, and
dosecat3.
When φ = 5 years, dosecat1 specifies 699 cells (620850.09
p-y). Hiroshima data is contained in 544 cells (573199.23
p-y), while 155 cells (47650.86 p-y) contain Nagasaki
data. Mean attained age ranges from 8.16 years to 96.84
years, and mean age-at-exposure ranges from 1 to 82.99
years. All individual doses within these cells are below 5
mSv. The weighted adjusted colon dose for the cell ranges
from 0.004 mSv to 0.25 mSv. As φ increases, cells move to
the baseline. For example at φ = 36.9 years, dosecat1 spec-
ifies 156 cells (104592.3 p-y) of which 115 cells
(95871.94 p-y) refer to Hiroshima and 41 cells (8720.36
p-y) to Nagasaki.
Likewise when φ = 5 years, dosecat2 specifies 560 cells
with 519832.84 p-y, of which 109 cells (95907.76 p-y)
contain Hiroshima data and 451 cells (423925.08 p-y)
contain Nagasaki data. Mean attained age ranges from
8.21 years to 93.32 years and mean age-at-exposure ranges
from 0.92 to 84.71 years. All individual doses within these
cells are below 5 mSv. The weighted adjusted colon dose
for the cell ranges from 0.25 mSv to 0.49 mSv. At φ = 36.9
years, dosecat2 specifies 115 cells (97536.25 p-y) of
which 28 cells (21631.85 p-y) refer to Hiroshima and 87
cells (75904.4 p-y) to Nagasaki.
Finally when φ = 5 years, dosecat3 specifies 1579 cells
with 548454.05 p-y, of which 780 cells (359098.67 p-y)
contain Hiroshima data and 799 cells (189355.38 p-y)
contain Nagasaki data. Mean attained age ranges from
8.12 years to 102.2 years and mean age-at-exposure ranges
from 0.93 to 91.56 years. All individual doses within these
cells are below 20 mSv. The weighted adjusted colon dose
for the cell ranges from 0.5 mSv to 20 mSv. At φ = 36.9
years, dosecat3 specifies 353 cells (97629.42 p-y) of
which 176 cells (63005.21 p-y) refer to Hiroshima and
177 cells (34624.21 p-y) to Nagasaki.
Note that whilst the dosecat variables are well defined on
the cells, they have no simple interpretation in terms of
individual doses within those cells. A cell with Dφ ≤ 0.025
(0.25 mSv) may contain individuals with lagged doses up
to 5 mSv; it is only the weighted average which is con-
strained below 0.25 mSv.
Each model is also constrained by λ = λ0(1 + ERR) ≥ 0
(equivalently ERR ≥ -1) in all cells, as the Poisson distribu-
tion is undefined if λiTi < 0.
Poisson regression [12] is based on minimising the model
Deviance, or equivalently minimising Σi [Ei - Oiln(Ei)]
where Ei and Oi are the expected and observed values.in
each cell. While Oi is given by the data, Ei depends on the
model and its parameter values. The data were placed on
a spreadsheet and the Excel tool Solver (Newton-Raphson
iteration) was used to optimise the parameters subject to
defined constraints.
With the control model, the minimal Deviance is inde-
pendent of φ. Once φ is fixed, the linear model has a
unique minimum Deviance. With other models, local
minima were compared to find the absolute minimum
DevModφ. Searches were conducted by partitioning the τ
axis as [0,1], [1,2]... [2j-1 ,2j]... [28,29], [29,∞) and begin-
ning iteration from (C, 0, 0, τj) where C represents the
control model Maximum Likelihood Estimate parameter
values, β and σ are initially set to 0 (β is constrained to 0
for the transient model); while τj is constrained to the jth
interval.
If model I is nested within model J by k parameter con-
straints, the likelihood ratio test for comparing the two
models at φ, LRTJ-I,φ = DevModI,φ – DevModJ,φ is approxi-
mately χ2 distributed on k df. At a given φ, LRTlin-con and
LRTtrans-con for comparing the linear and transient models
with the control model each have 1 df, while LRT2p-con for
comparing the two-phase model with the control model
has 2 df. Note that LRT2p-trans, LRT2p-lin, and LRTtrans-lin
have 1 df as each nested pair is defined by a single param-
eter constraint, and that LRT2p-con = LRT2p-lin + LRTlin-con.
For each model J  (linear, transient, and two-phase), I
found best fits by choosing φ = φm to maximise LRTJ-con,φ
(equivalently to minimise DevModJ,φ) either absolutely or
with the constraint that ERR at Dφ = 0.025 be ≥ 0. The
value of φm may vary with the model.
Profile Likelihood Confidence Intervals for ERR were
computed at specified values of Dφ. For example, in the
two-phase model ERR depends on Dφ and T = (β,σ,τ)
whilst Deviance depends on (φ,C,T) where C is the vector
of control parameters. With φ fixed, let Vφ be the set of T
which can be ruled out with 95% confidence, as all
choices of C give Dev(φ,C,T) – DevModφ > K, where K ~
7.8147 satisfies χ3
2(K) = 0.95. Define Minφ (respectively
Maxφ) as the largest v (smallest w) for which the constraint
ERR(Dφ,T) < v (> w) implies T ∈ Vφ. The interval (Minφ,
Maxφ) is taken as a 95% CI for ERR(Dφ) in the two-phase
model.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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Results
For each cancer site and for φ = 5, 6, ... 44, models were fit-
ted to the 0 – 20 mSv male/female (M/F) data.
For the linear model only, I estimated ERR0.025,φ by fitting
the model to the restricted subcohort of cells with mean
weighted adjusted colon dose ≤ 0.5 mSv; ERR1,φ  was
obtained from fitting the 0 – 20 mSv data, as with all other
modelling.
More precise optimal latencies φm, 95% CI's for
 and  , and Goodness-of-Fit (GoF)
statistics were determined for the nested models, includ-
ing separate male and female results. The category model
(M/F) was then fitted using the optimal latencies from the
two-phase model.
Results are now outlined for specific cancers (M/F).
Stomach
The linear model is never significant against the control
model, but Figure 2 suggests two distinct latency periods:
5 ≤ φ ≤ 21, and 29 ≤ φ ≤ 41. Outside these periods, the
nested models show no significant improvement on the
control model. In both periods, the two-phase and tran-
sient models improve on the control model. The two-
phase model significantly improves on the transient and
linear models when 5 ≤ φ ≤ 21 and on the linear model
when 29 ≤ φ ≤ 41. For the two-phase model, ERR0.025,φ and
ERR1,φ are both positive when 5 ≤ φ ≤ 21, and negative
when 29 ≤ φ ≤ 41 (Figure 3).
For the linear model (Table 1) φm = 6.66 is optimal in the
region of ERR ≥ 0, but the model is not significant against
the control model. For the transient model (Table 2) φm=
11.85 is optimal within the range for which ERR0.025,φ ≥ 0,
but ERR is not significantly positive. The optimal latency
for the two-phase model (Table 3) is φm = 11.89, when
comparison with the control model has LRT2p-con = 21.190
(2 df), and comparisons with the transient and linear
models have LRT2p-trans = 15.684 (1 df) and LRT2p-lin =
19.643 (1 df). Each LRT is highly significant. The two-
phase model gives ERR0.025,φ = 0.391 with 95%CI (0.077,
0.857) while ERR1,φ = 0.459 (0.113, 0.942). When Dφ =
Dmax = 0.012, ERR attains a local maximum of 0.539
(0.171, 1.037).
Applying the category model (Table 4) with φ = 11.89
gives LRTcat-con = 21.590 (3 df) and both β1 and β3 are
significantly positive.
The models pass Goodness-of-Fit tests with Dev, but Pear-
son Chi-Square exceeds df due to one case in a cell with T
= 0.4 p-y. The two-phase model is preferable to its nested
alternatives by LRT comparisons, and clearly distinguishes
the latency periods as regions of positive and negative
ERR. At the optimal latency, R = 1 + σ/β= 262.62.
Liver
There are two distinct latency periods outside which the
models are insignificant (Figure 4). When 10 ≤ φ ≤ 23 the
two-phase model improves on the transient, linear, and
control models, and ERR0.025,φ and ERR1,φ are negative in
all three models (Figure 5). When 32 ≤ φ ≤ 41 the two-
phase model improves on the transient, linear, and con-
trol models, and ERR0.025,φ and ERR1,φ are non-negative in
all three models. When 34 ≤ φ ≤ 43 the transient and linear
models each improve on the control model with positive
ERR, and when 34 ≤ φ ≤ 38 the transient improves on the
linear model.
The optimal latencies are 38.58 (linear), 36.90 (tran-
sient), and 36.90 if the two-phase model is optimised
with ERR0.025,φ ≥ 0. At φm = 36.90 the two-phase model has
LRT2p-con = 34.874 while LRT2p-trans = 16.755 and LRT2p-lin
= 27.642, all highly significant comparisons. At the opti-
mal latency, the two-phase model gives ERR0.025,φ = 1.099
(0.264, 2.374) while ERR1,φ = 1.428 (0.481, 2.954). The
local maximum ERR occurs when Dφ = 0.013. Estimates
from the transient and linear models are comparable.
Applying the category model with φ = 36.90 gives LRTcat-
con = 33.844 and β1, β2, and β3 are all significantly positive.
If "city" is included as a control, LRTcat-con = 34.939, β1 =
1.35 (0.72, 2.23), β2 = 0.73 (0.14, 1.60), β3 = 1.39 (0.70,
2.34).
The models pass both GoF tests. The two-phase model is
preferable to its nested alternatives by LRT and gives wider
periods of significant improvement on the control model,
distinguished as regions of positive and negative ERR. At
the optimal latency R = 204.11.
Lung
The linear model is never significant against the control
model (Figure 6). The transient improves on the linear
and control models when 5 ≤  φ  ≤ 38. The two-phase
improves on the linear and control models when 5 ≤ φ ≤
21 and when 24 ≤ φ ≤ 38, and on the transient model
when 32 ≤ φ ≤ 38. When 5 ≤ φ ≤ 21 the transient and linear
models give positive ERR0.025,φ and ERR1,φ (Figure 7) as
does the two-phase when 7 ≤ φ ≤ 21. When 22 ≤ φ ≤ 41
ERR0.025,φ and ERR1,φ are negative in the two-phase and
transient models.
Optimal latencies are 16.90 (linear), 13.60 (transient),
and 13.60 if the two-phase model is optimised with posi-
tive ERR0.025. At φm = 13.60 the transient model has LRT-
trans-con = 15.701 while LRTtrans-lin = 14.394, both highly
ERR
m 0 025 ., φ ERR
m 1,φEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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significant. At this latency the transient model gives
ERR0.025,φ = 0.790 (0.195, 2.006) while ERR1,φ = 0.796
(0.189, 1.985). The two-phase model does not improve
the transient and gives comparable ERR with somewhat
wider CI's. It does improve on the linear model with
LRT2p-lin = 14.734 and gives R = 86.39.
Applying the category model with φ = 13.60 gives LRTcat-
con = 19.304 and β1, β2, and β3 are all significantly positive.
The 3 nested models pass both GoF tests. The transient
model is preferable here.
Colon
None of the models give significant positive response for
the M/F data (Figure 8, Figure 9). The transient model has
occasional weak negative response.
Stomach cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 2
Stomach cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. LRT is the likelihood ratio test for comparison of 
the indicated pair of models evaluated at fixed latency φ, and is χ2 distributed on 1 d.f. (red line shows LRT2p-lin for comparing 
the two-phase and linear models, green line shows LRTtrans-lin for comparing transient and linear models, blue line shows LRTlin-
con for comparing linear and control models) LRT values above 3.84 are significant at p = 0.05, above 6.63 at p = 0.01, above 
10.83 at p = 0.001. Other LRT can be derived at each φ value, e.g. LRT2p-con = LRT2p-lin + LRTlin-con and LRTtrans-con = LRTtrans-lin 
+ LRTlin-con while LRT2p-trans = LRT2p-lin - LRTtrans-lin. Latency φ (in years) is used in defining the lagged dose Dφ = DS86 weighted 
adjusted colon dose if Time-Since-Exposure ≥ φ, Dφ = 0 otherwise. Models specify the Excess Relative Risk ERR as a function of 
Dφ while controlling for gender, log attained age, and age-at-exposure categories. Control: ERR = 0 Linear: ERR = βDφ; control 
model nested by β = 0. Transient: ERR = σDφ e(-τDφ) with τ ≥ 0; linear model nested by τ = 0. Two-phase: ERR = βDφ + σDφ e(-
τDφ) with τ ≥ 0; linear model nested by σ = 0; transient model nested by β = 0.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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Uterus
The linear model is never significant against the control
model (Figure 10). When 12 ≤ φ ≤ 16 the transient and
two-phase models both improve on the control model,
and ERR is negative in all three models (Figure 11). When
24 ≤ φ ≤ 33 ERR0.025,φ and ERR1,φ are positive in the two-
phase and transient models. At the optimal latency φ =
26.91 (in the region of positive ERR) both the two-phase
and transient models are weakly significant against the
linear and control models. The 95%CI's do not exclude
negative ERR.
Applying the category model with φ = 26.91 gives the
weak result LRTcat-con = 8.077 with only β1 significantly
positive.
All-solid
When 22 ≤ φ ≤ 23 the two-phase model is significant
against transient, linear, and control models (Figure 12)
and ERR is negative in all models (Figure 13). When 39 ≤
φ  ≤ 44 the transient model improves on the control
model, and when 42 ≤ φ ≤ 43 the transient and two-phase
improve on the linear and control models. When 37 ≤ φ ≤
44 ERR is positive in all models. The optimal latency in all
three nested models is φm = 43.86, at which all are signifi-
cant against the control model and the transient and two-
phase are significant against the linear model.
At φm = 43.86 the transient model has LRTtrans-con = 16.781
and LRTtrans-lin = 11.753, both highly significant, with
ERR0.025,φ = 0.271 (0.070, 0.509) while ERR1,φ = 0.300
Stomach cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 3
Stomach cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. For each model (two-phase in red, transient in 
green, linear in blue) fitted at fixed latency φ, series 1 (solid lines) shows the Excess Relative Risk ERR1 (ERR at 10 mSv lagged 
dose); series 025 (dotted lines) shows ERR0.025 (ERR at 0.25 mSv lagged dose). For latency φ and model definitions see Figure 2. 
For Linear 025 only, ERR0.025 is estimated from the 0 – 0.5 mSv data.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
Page 8 of 25
(page number not for citation purposes)
(0.034, 0.633). The two-phase model has LRT2p-con  =
17.925, LRT2p-lin = 12.896, both highly significant, while
LRT2p-trans = 1.143 is not significant. ERR0.025,φ = 0.269
(0.051, 0.538) while ERR1,φ = 0.272 (-0.044, 0.662). The
linear model has LRTlin-con = 5.029 and ERR1,φ = 0.259
(0.030, 0.522). If applied to the 0 – 0.5 mSv data, the opti-
mal latency is φm = 41.78 at which LRTlin-con = 5.562 and
ERR0.025,φ = 0.175 (0.028, 0.344).
At φ = 43.86 the category model has LRTcat-con = 16.311
while β2 and β3 are significantly positive.
The models pass both GoF tests. The transient model is
preferable here, for simplicity.
Comparison with LSS12
The ERR values found here by applying non-linear models
to the 0 – 20 mSv subcohort and optimising latency are
several orders of magnitude above those derived by
extrapolating from results for a linear model applied with
fixed 5 year lag to the entire dose range of A-bomb survi-
vors, as in LSS12 [4] whose Tables AII (Male/Female), AIII
(Male) and AIV (Female) show ERR/Sv (organ dose). If a
linear model is applied to a single dataset, ERR for d mSv
will be (d/1000)(ERR/Sv). Extrapolations of this type are
inherent in the ICRP estimate of the risks arising from low
doses, which underpin its recommended annual dose lim-
its.
Comparisons are shown in Table 5. Significant discrepan-
cies occur at 10 mSv (ERR1) and 0.25 mSv (ERR0.025) with
the two-phase model for stomach, liver, and lung; and
with the transient model for liver and lung.
Table 1: Linear modela
Stomach Liver Lung
gender M/F M/F M/F
casesb 1482 540 524
φm
c 6.66 38.58 16.90
ca Dφ > 0d 1412 172 494
LRTlin-con
e 2.09 11.21 2.26
ERR1,φ
fg 0.09 (-0.03, 0.22) 0.69 (0.25, 1.26) 0.16 (-0.05, 0.42)
Devh 1680.64 1258.02 1052.43
Chi-sqi 3205.08 2389.85 2500.37
dfj 2992 2992 2992
Excessk 38.13 27.17 23.20
Colon Uterus All solid
gender M/F F M/F
casesb 214 263 4379
φm
c 43.91 6.12 43.86
ca Dφ > 0d 33 262 365
LRTlin-con
e 0.19 0.51 5.03
ERR1, φ
fg 0.17 (-0.44, 1.17) 0.10 (-0.16, 0.44) 0.26 (0.03, 0.52)
Devh 719.80 638.46 2133.03
Chi-sqi 3497.50 1010.56 2769.51
dfj 2992 1513 2992
Excessk 1.51 8.88 25.01
a 0 – 20 mSv subcohort, Excess Relative Risk ERR = βDφ with β constrained by 1 + ERR  ≥ 0 for all data cells. Dφ is the weighted adjusted colon dose 
(neutron RBE = 10), lagged by φ years, in 10 mSv units. The control model is nested by β = 0.
b deaths in the subcohort from the specified cancer
c Latency φm is chosen in the range 5 – 44 years. to minimise linear model Deviance for the given cancer site and gender. Where italicised, φm 
minimises Dev subject to ERR ≥ 0, equivalent to β ≥ 0
d deaths in the subcohort from the specified cancer, for which Dφ > 0 where φ = φm
e The likelihood ratio test LRTlin-con compares the fitted linear model with the control model at φm and is χ2 distributed on 1 degree of freedom
f ERR1,φ is the Excess Relative Risk at Dφ = 1 with φ = φm
g 95% Profile Likelihood Confidence Intervals are calculated with φ fixed at φm
h Deviance of the fitted model
i Pearson Chi-Square of the fitted model
j Degrees of Freedom of the fitted model
k difference between Observed (= Expected) cases and the number expected if Dφ is set to 0 in every cell after fitting the modelEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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Estimates of ERR1 from the non-linear models are 2 to 3
orders of magnitude above extrapolations from LSS12; for
ERR0.025 the discrepancy is 3 to 4 orders of magnitude.
Dosimetry
As a first step towards understanding how dosimetry
errors may affect these results, the models were fitted to
portions of the 0 – 20 mSv data for the liver. Models were
refined to control for "city", although this had little
impact. There are 173 data cells with weighted adjusted
colon dose = 0. If these cells are deleted from the 0 – 20
mSv subcohort and analysis is restricted to the remaining
2838 cells, fitting the two-phase and linear models for the
liver (M/F) at φ = 36.90 years gives LRT2p-con = 37.639,
LRT2p-lin = 30.095, and ERR1 = 1.478 (0.52, 3.04). Thus the
results for the liver are not caused by any special features
of the zero-dose cells.
Alternatively, choose 0 = x0 < x1 < x2 < ... < x9 < x10 = 20
mSv. Define Si as the set of data cells in the 0 – 20 mSv
Table 2: Transient modela
Stomach Liver Lung
gen M/F M/F M/F
φm
b 11.85 36.90 13.60
ca Dφ > 0 1323 231 506
σc 77.56 33.51 34.72
τ 129.19 3.56 3.78
LRTtrans-lin
d 4.49 10.89 14.39
LRTtrans-con 5.91 18.12 15.70
ERR0.025,φ
e 0.08 (-0.11, 0.23) 0.77 (0.18, 1.67) 0.79 (0.20, 2.01)
ERR1,φ 0.00 (-0.06, 0.16) 0.95 (0.28, 1.99) 0.80 (0.19, 1.99)
Dmaxf 0.01 0.28 0.27
ERRDmax,φ 0.22 (-0.04, 0.61) 3.46 (1.00, 7.11) 3.38 (0.90, 8.43)
Dev 1676.81 1251.10 1039.00
Chi-sq 3397.32 2436.33 2728.08
df 2991 2991 2991
Excess 91.23 95.89 214.39
Colon Uterus All solid
gen M/F F M/F
φm
b 43.98 26.91 43.86
ca Dφ > 0 28 127 365
σc 26.69 275.88 11.89
τ 5.98 132.36 3.68
LRTtrans-lin
d 3.17 4.48 11.75
LRTtrans-con 3.20 4.48 16.78
ERR0.025,φ
e 0.58 (-0.25, 1.85) 0.25 (-0.09, 1.13) 0.27 (0.07, 0.51)
ERR1,φ 0.07 (-0.49, 1.71) 0.00 (-0.23, 1.06) 0.30 (0.03, 0.63)
Dmaxf 0.17 0.01 0.27
ERRDmax,φ 1.64 (-0.60, 6.10) 0.77 (-0.54, 5.35) 1.19 (0.41, 2.06)
Dev 716.79 634.49 2121.27
Chi-sq 3473.93 1051.37 2765.95
df 2991 1512 2991
Excess 8.24 19.99 78.00
a 0 – 20 mSv subcohort, Excess Relative Risk ERR = σDφ   with τ  ≥ 0 and σ,τ constrained by 1 + ERR ≥ 0 for all data cells; for Dφ see Table 
1. The linear model is nested by τ = 0; the control model is nested by σ = 0.
b chosen in the range 5 – 44 years. to minimise transient model Deviance; where italicised φm minimises Dev subject to ERR ≥ 0, equivalent to σ ≥ 0.
c At φm, σ and τ are the fitted Maximum Likelihood Estimate parameter values.
d At φm, the likelihood ratio test LRTtrans-lin compares the transient with the linear model and LRTtrans-con compares the transient model with the 
control model. Each LRT is χ2 distributed on 1 degree of freedom.
e At φm, ERRD,φ is the Excess Relative Risk at Dφ = D, with 95% Profile Likelihood Confidence Interval.
f At φm, Dmax = 1/τ is the value of D which maximises ERRD,φ
g n/a indicates no lower limit could be calculated with 1 + ERR ≥ 0
Other definitions and total cases as Table 1.
e
D () −τ φEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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subcohort for which the weighted adjusted colon dose
does not fall in the interval [xi-1, xi]. The xi may be chosen
so that the Si have roughly equal p-y of observation. Then,
fitting the two-phase and linear models for the liver (M/F)
with φ = 36.9 to the reduced datasets Si gives LRT2p-lin and
ERR1 values as shown in Table 6. LRT2p-lin values are ≥
18.94 (1 df) and ERR1 is fairly stable, varying from 1.21 to
1.74.
The DS86 dosimetry used here and in LSS12 was re-inves-
tigated by a Joint Working Group using physical measure-
ments, resulting in a new dosimetry system DS02 [11]. A
Table 3: Two-phase modela
Stomach Liver Lung
gen M/F M/F M/F
φm
b 11.89 36.90 13.60
ca Dφ > 0 1311 231 506
βc 0.46 1.43 0.44
σ 119.96 290.09 37.92
τ 82.67 76.82 4.47
LRT2p-trans
d 15.68 16.76 0.34
LRT2p-lin 19.64 27.64 14.73
LRT2p-con 21.19 34.87 16.04
ERR0.025,φ 0.39 (0.08, 0.86) 1.10 (0.26, 2.37) 0.86 (0.14, 3.34)
ERR1,φ 0.46 (0.11, 0.94) 1.43 (0.48, 2.95) 0.88 (0.12, 3.36)
Dmaxe 0.01 0.01 0.23
ERRDmax,φ 0.54 (0.17, 1.04) 1.41 (0.50, 2.86) 3.23 (0.09, 9.39)
Dev 1661.53 1234.35 1038.66
Chi-sq 3408.01 2447.95 2770.40
df 2990 2990 2990
Rf 262.62 204.11 86.39
Excess 390.00 126.36 224.43
Colon Uterus All Solid
gen M/F F M/F
φm
b 20.28 26.91 43.86
Dφ > 0 184 127 365
βc -0.74 0.47 -0.62
σ 11.32 198.10 13.10
τ 2.66 81.12 2.32
LRT2p-trans
d 1.32 1.83 1.14
LRT2p-lin 3.01 6.31 12.90
LRT2p-con 3.54 6.31 17.93
ERR0.025,φ 0.25 (-0.44, 1.46) 0.66 (-0.10, 2.44) 0.27 (0.05, 0.54)
ERR1,φ 0.05 (-0.53, 1.15) 0.47 (-0.32, 2.12) 0.27 (-0.04, 0.66)
Dmaxe 0.32 0.01 0.35
ERRDmax,φ 1.31 (-0.71, 1.51) 0.90 (-0.17, 2.96) 1.59 (0.03, 2.54)
Dev 716.45 632.66 2120.13
Chi-sq 3339.24 1047.11 2759.48
df 2990 1511 2990
Rf -14.36 425.41 -19.98
Excess 29.34 45.89 74.59
a 0 – 20 mSv subcohort, Excess Relative Risk ERR = βDφ + σDφ   with τ ≥ 0 and β,σ,τ constrained by 1 + ERR  ≥ 0 for all data cells; for Dφ 
see Table 1. The transient model is nested by β = 0; the linear model is nested by σ = 0 or by τ = 0; the control model is nested by β = σ = 0.
b chosen in the range 5 – 44 years. to minimise two-phase model Deviance; where italicised φm minimises Dev subject to ERR0.025,φ ≥ 0, a weaker 
condition than β, σ ≥ 0.
c At φm, β, σ and τ are the fitted Maximum Likelihood Estimate parameter values.
d At φm, the likelihood ratio tests LRT2p-trans and LRT2p-lin compare the two-phase with the transient and linear models (χ2 on 1 df); and LRT2p-con 
compares the two-phase model with the control model (χ2 on 2 df)
e At φm, Dmax is the value of D giving a local maximum of ERRD,φ
f R = 1 + σ/β
Other definitions as in Table 2
e
D () −τ φEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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dataset using DS02 and enabling comparison with DS86
was released by RERF last year and can be downloaded as
DS02can.dat from the RERF website [9]. However, the
cancer mortality fields in this dataset only show deaths
from solid cancers (combined), liquid cancers, and leu-
kaemia. Investigation of the stomach, liver, and lung as
individual sites is not possible from this public dataset.
Furthermore, the stratification of the new dataset differs
from that in LSS12 and it is not possible to simply read off
the DS02 values for cells in the LSS12 data.
Nonetheless for those cells in the DS02 dataset which
have a DS86 dose, the weighted adjusted DS02 colon dose
using neutron RBE = 10, shown as "cola02w10", can be
compared with the corresponding DS86 dose variable
shown as "cola86w10".
Only 11 cells, with 13.83 p-y and no solid cancer deaths,
have cola02w10 < 0.005 Sv and cola86w10 ≥ 0.005 Sv.
Only 5 cells, with 11.24 p-y and no solid cancer deaths,
have cola02w10 ≥ 0.005 Sv and cola86w10 < 0.005 Sv.
For cells with cola86w10 ≥ 0.005 Sv the ratio θ =
cola02w10/cola86w10 varies from 0.216 to 1.925 with
mean 1.08 and standard deviation 0.082. There are only 7
cells, with 10.47 p-y and no solid cancer deaths, for which
θ < 0.5. Likewise 92 cells, with 195.84 p-y and 3 solid can-
cer deaths, have θ > 1.5. In the subcohort with 0.005 Sv ≤
cola86w10 ≤ 0.02 Sv, θ varies from 0.216 to 1.27 with
Table 4: Category modela
Stomach Liver Lung
gen M/F M/F M/F
φm
b 11.89 36.90 13.60
Dφ > 0 1311 231 506
T1
c 505007.81 104710.40 452429.89
T2 433148.43 100577.71 389939.77
T3 453123.28 97629.42 408114.01
LRTcat-con
d 21.59 33.84 19.30
β1
e 0.48 (0.21, 0.81) 1.30 (0.68, 2.15) 0.96 (0.17, 2.46)
β2 0.16 (-0.08, 0.46) 0.85 (0.25, 1.75) 1.84 (0.66, 4.08)
β3 0.42 (0.16, 0.75) 1.39 (0.70, 2.34) 1.33 (0.38, 3.11)
Dev 1661.13 1235.38 1035.39
Chi-sq 3391.69 2451.56 3111.30
df 2990 2990 2990
Colon Uterus All solid
gen M/F F M/F
φm
b 20.28 26.91 43.86
Dφ > 0 184 127 365
T1
c 342887.98 128431.04 24656.43
T2 288767.71 153667.68 21860.18
T3 307331.28 145793.72 21917.87
LRTcat-con
d 1.57 8.08 16.31
β1
e 0.07 (-0.40, 0.95) 0.92 (0.19, 2.08) 0.13 (-0.06, 0.34)
β2 0.32 (-0.31, 1.52) 0.28 (-0.30, 1.29) 0.43 (0.16, 0.74)
β3 0.02 (-0.44, 0.89) 0.52 (-0.08, 1.48) 0.29 (0.06, 0.56)
Dev 718.42 630.89 2121.74
Chi-sq 3625.26 1038.26 2772.40
df 2990 1511 2990
a 0 – 20 mSv subcohort, Excess Relative Risk ERR = β1dosecat1 + β2dosecat2 + β3dosecat3 with βi constrained by 1 + βi ≥ 0; dosecat1 = 1 if 0 < Dφ ≤ 
0.025, and = 0 otherwise; dosecat2 = 1 if 0.025 < Dφ ≤ 0.05, and = 0 otherwise; dosecat3 = 1 if 0.05 < Dφ, and = 0 otherwise. The Control model is 
nested by β1 = β2 = β3 = 0.
b Latency φm is chosen from the results of the two-phase model (Table 3)
c At φm, Tj is the p-y observation for which dosecatj = 1, j = 1,2,3
d At φm, the likelihood ratio test LRTcat-con compares the category model with the control model (χ2 on 3 df)
e At φm, βi are the fitted Maximum Likelihood Estimate parameter values, with 95%CI's
Other definitions as in Table 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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mean 1.026 and standard deviation 0.077. There are 15
cells with 78.5 p-y and 2 solid cancer deaths, for which θ
< 0.8, and 9 cells with 9.88 p-y and 1 solid cancer death,
for which θ > 1.2
Thus if DS02 is an accurate estimate of the flash dose,
there is virtually no misclassification of DS86 between the
categories "above 5 mSv" and "below 5 mSv", and above
5 mSv the DS86 dose is a reasonable estimate, though 8%
below DS02 on average.
The scope in this paper for misclassification of the dose is
therefore reduced if doses below 5 mSv are taken as base-
line and doses from 5 to 20 mSv are taken as a single cat-
egory which is then analysed with latency. While that
approach is too crude to detect non-linearity, it gives very
similar results for the liver to those found with the linear
model.
As shown in Table 1 the optimal latency for the liver (M/
F) using the linear model is φ = 38.58, for which compar-
ison with the control model has LRTlin-con = 11.21, β =
ERR1 = 0.69 (0.25, 1.26). Now define E = 1 if Time-Since-
Exposure ≥ 38.58 and 5 mSv ≤ colon dose ≤ 20 mSv, E = 0
otherwise. As Time-Since-Exposure is known, errors in E
can only arise if doses below 5 mSv were misclasssified as
above 5 mSv, or vice versa. Fitting the model defined by
ERR = γE to the liver (M/F) data for the 0 – 20 mSv dose
range and comparing with the control model (γ = 0) gives
LRT = 11.04, γ = 0.67 (0.24, 1.21). Thus the results for the
linear model can be reproduced with a two-category
model using a cutpoint of 5 mSv, and these categories are
almost identical whether defined by DS86 or DS02.
As a further test, the liver data were modelled in the
extended DS86 dose range 5 mSv – 500 mSv, where DS86
and DS02 are in reasonable agreement. The two-phase
Liver cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 4
Liver cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. Axes and model definitions as in Figure 2.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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model is a significant improvement on the linear model at
latency φ = 36.9 years, with LRT2p-lin = 10.37 (1 df) and
ERR1 = 0.74 (0.10, 1.79).
Similar results for the liver are obtained from the 0 – 500
mSv dose range. The two-phase model is a significant
improvement on the linear model at latency φ = 36.9
years, with LRT2p-lin = 16.86 (1 df) and ERR1 = 0.76 (0.15,
1.66).
For comparison, the results for the liver obtained from the
0 – 20 mSv dose range at latency φ = 36.9 years, are LRT2p-
lin = 29.67 (1 df) and ERR1 = 1.46 (0.50, 3.00). Similar
results when "city" is omitted from the model are shown
in Table 3.
The DS02 public dataset does not show the liver but does
allow modelling of all-solid cancers. The subcohort S
defined by cola02w10 ≤ 0.02 and Time-Since-Exposure ≤
45.39 years (the maximum value in the 0 – 20 mSv sub-
cohort of LSS12 data) has 1682335.39 p-y and 4363 cases,
roughly comparable to the LSS12 subcohort analysed
with DS86 in this paper. Models were defined as previ-
ously, but using cola02w10 in place of the DS86 weighted
adjusted colon dose. None of the cells in S contain Naga-
saki factory workers. Controls for "city" and "ground dis-
tance category" (proximal or distal) were introduced,
Liver cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 5
Liver cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. Axes and model definitions as in Figure 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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though they had little impact. If the linear model is fitted
to S with latency φ = 43.29 years then LRTlin-con = 3.79 (1
df). For the two-phase model LRT2p-con = 10.49 (2 df) and
LRT2p-lin = 6.70 (1 df), again showing non-linearity. ERR1
= 0.223 (-0.07, 0.58). For the DS86 results, Table 3 shows
ERR1 = 0.272 (-0.04, 0.66) at latency 43.86 years.
The estimates of ERR1 for all-solid cancers are similar
whether derived from the 0 – 20 mSv subcohort of LSS12,
or the comparable 0 – 20 mSv subcohort of the DS02
data.
The DS02 data contains an additional 10 years of follow-
up. Non-linearity is still present in the extended cohort.
Define the subcohort T by cola02w10 ≤ 0.02 without
restricting Time-Since-Exposure. At latency 43.29 years
the linear model is indistinguishable from the control
model (LRT = 0.47) but the two-phase model has LRT2p-
con = 9.49 (2 df) and LRT2p-lin = 9.02 (1 df). ERR1 = 0.08 (-
0.07, 0.26).
Discussion
This paper begins from the publicly available data, and I
do not know if a comparable analysis of the anonymous
individual data would show similar results.
In re-analysing portions of the 1950–90 grouped data, the
approach here has four features.
1) To predict risks at 10 mSv, the 0 – 20 mSv data is ana-
lysed directly.
2) A variable lag period is used to analyse latency.
3) Dosimetry data is not reduced to categories before
modelling. Dose is taken as a numerical variable, defined
Lung cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 6
Lung cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. Axes and model definitions as in Figure 2.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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on the grouped data cells, but results are also tested in a 4-
category model with baseline defined by Dφ = 0 and cut-
points which roughly equipartition the p-y in non-base-
line categories.
4) Linearity of the dose response is tested by nesting
within more complex models.
With a fixed 5 year lag, none of the cancers considered
here show significant effects in the 0 – 20 mSv dose range
using a linear model. Allowing latency to vary in this
model gives significant positive responses for the liver and
all-solid cancers.
Latency reflects biochemical changes required after initial
radiation if mutant cells are to progress and form a
tumour eventually identified as cause of death, and histor-
ical changes in environmental factors which interact with
radiation for a particular cancer. Thus latency may be
organ and gender specific.
Rothman [13] illustrates how ignoring latency may mask
important effects, whether or not the original exposure
was brief. Analysis using the lagged dose Dφ is a simple
approach depending on only one parameter. The
response might be clearer by modelling the effect of D*w,
with w some more general function of Time-Since-Expo-
sure. Such models have been applied to lung cancer mor-
tality in uranium miner cohorts [14,15].
If the linear model were appropriate throughout the low
dose region, we might expect ERR0.025,φ ~ 0.025(ERR1,φ)
Lung cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 7
Lung cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. Axes and model definitions as in Figure 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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whatever data were used to estimate each ERR. In fact, the
ERR values are often comparable. Two non-linear models
give significant improvements in the 0 – 20 mSv dose
range for the stomach, liver, lung, uterus and all-solid can-
cers, and for various gender specific sites. These improve-
ments are strong, for example p < 0.001 when comparing
the two-phase and linear models (M/F) for stomach, liver,
lung, and all-solid; and p < 0.000001 for the liver.
Unlike the linear and control models, the transient and
two-phase models require extensive computation as the
Deviance may have multiple local minima at any choice
of latency φ (fixed when fitting the model). Computation
involves a search for local minima, selection of the mini-
mum Deviance at φ, and then a comparison amongst
these minima for different φ values. The optimal φ is cho-
sen to give the absolute minimum Deviance, with or with-
out the constraint that ERR0.025  be non-negative. The
search is streamlined by restricting φ to 5, 6, ... 44 and later
refined to consider all φ (to 2 decimal places) in a range
which appears likely to contain the optimal value.
I do not know of any general analytical method which
might limit the total number of local minima at fixed φ in
this data. Instead, the τ axis is partitioned (see Methods).
Fitting the model with τ constrained to an interval typi-
cally yields a τ value at either endpoint, reflecting the con-
straint, except for those intervals which contain τ values at
which the Deviance attains a local minimum.
Searches begin from the control parameter values which
optimise the control model, while τ is confined to the rel-
evant interval and β,σ are initially set to 0. Conceivably,
this choice of initial conditions may cause the Newton-
Raphson iteration to miss some local minima, though
testing other initial conditions did not detect any other
Colon cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 8
Colon cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. Axes and model definitions as in Figure 2.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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solutions. In any case the minimum Deviance at any par-
ticular φ can be no higher than the values found here, so
any missing minima could only strengthen the evidence
of non-linearity.
Fitting the two-phase model to the lung data illustrates
these issues. When φ = 13 three local minima are detected.
At τ = 4.51, Dev = 1040.35. At τ = 13.86, Dev = 1040.87.
At τ = 175.63, Dev = 1050.25. The minimum Dev at φ =
13 is thus 1040.35. The linear model has Dev = 1053.64.
Thus LRT2p-lin for comparing the two-phase and linear
models is 1053.64 – 1040.35 = 13.29, and it is this value
which is displayed in Figure 6 when φ = 13. Likewise the
ERR value computed at this minimum Dev is displayed in
Figure 7 when φ = 13. The resulting graphs indicate the
region to be searched for an optimal choice of φ, subject
to the constraint ERR ≥ 0. This optimum is φ = 13.6, the
value shown in Table 3. At this latency there are again 3
local minima, two of which have similar Dev. At φ = 13.6
the minimum at τ = 4.45 with Dev = 1038.58 has ERR1 =
0.88 while the local minimum at τ = 13.54 with Dev =
1039.26 has ERR1 = 1.10. Note that while τ varies widely
without appreciable change in Dev, ERR1 is much more
stable. In this example, the 95%CI is (0.12, 3.36). For this
reason, ERR is a much better focus for analysis than the
model parameters themselves.
Confidence intervals for ERR are often somewhat wider in
the two-phase model than in the simpler transient model
which is sufficient to describe the lung and all-solid (M/F,
F) data. However, as well as improving the fit for the stom-
ach, liver and all-solid (M) the two-phase model gives a
more coherent account of the latency regions of signifi-
cant positive or negative dose response.
Colon cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 9
Colon cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. Axes and model definitions as in Figure 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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Linear extrapolation of the LSS12 results shows almost no
response at the doses considered here. Whilst LSS12 uses
organ doses and a different system of controls, these fac-
tors do not account for the large discrepancy in risk esti-
mates. Alternative controls affect the estimates by a factor
of 2 or less, and the use of organ doses has even less
impact. Significant discrepancies arise when the dose
range is restricted to 0 – 20 mSv and latency is included in
the analysis.
Stewart and Kneale [16] found evidence of selection bias
in the LSS 1950 – 1985 cohort, thought to reflect the fact
that only those victims able to survive from 1945 – 1950
were eligible to enter the cohort. The test group used by
Stewart and Kneale to detect bias included less than 4% of
the total cohort but had nearly 30% of high doses (> 1000
mSv). It is plausible that such bias would be reduced in
the 0 – 20 mSv subcohort, but I cannot test this from the
publicly available RERF data.
Pierce and Preston [17] analysed all-solid cancer inci-
dence in Japanese survivors from the 1958 – 1994 tumour
registry data for the range 0 – 500 mSv, using a linear ERR
model based on colon dose and a categorical model with
cutpoints 0, 5, 20, 100, 200, 250, 300, 400 mSv (colon
dose). Estimates correspond to ERR ~ 0.006 at 10 mSv.
Likewise, if the linear model here is applied to all-solid
cancer mortality (1950–90) in the 0 – 500 mSv dose range
with latency 5 years, ERR1 = 0.004 with LRT = 8.58.
Pierce and Preston focus on survivors who were exposed
relatively near the hypocentres of the A-bombs and
exclude distal survivors ( ≥ 3 km distant) on the grounds
that they had higher baseline cancer rates and that some
lifestyle cancer risk factors correlate with urban-rural dis-
Uterine cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 10
Uterine cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. Axes and model definitions as in Figure 2.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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tinctions, though cigarette smoking had almost no corre-
lation with estimated dose or distance from the
hypocentre. Excluding the distal group lowered the base-
line by about 5% in their data. Although that is significant
in relation to the estimates of ERR in the RERF studies, it
is marginal compared to the ERR values found here with
the latency models.
The 0 – 20 mSv subcohort contains many proximal as well
as distal survivors (10,159 proximal survivors in the inci-
dence dataset had doses below 5 mSv). The results here
may of course reflect other risk factors which may corre-
late and/or interact with radiation dose, but which could
only be approached through the individual data. Investi-
gation of possible confounders should also consider
latency and non-linear models such as those analysed
here, given their clear superiority to the linear model with
fixed 5 year lag, for the low-dose grouped data.
This paper is based on the DS86 dosimetry and the results
could reflect dosimetry errors, arising from incorrect esti-
mation of the flash dose or by omitting other radiation
sources. The doses received in Hiroshima and Nagasaki
include the flash dose (used here), induced radioactivity
in building materials or soil which persisted for several
weeks, "black rain" which fell in the immediate aftermath
of the bombings, natural background radiation, global
fallout from atmospheric weapons tests, occupational and
medical exposures. The public data does not include any
individual occupational or medical exposures. Natural
background and global fallout should not be correlated
with the exposures arising directly from the bombs in
1945, and would be expected to bias results towards the
null. Doses from induced radioactivity and "black rain"
could be relevant, but currently available RERF public
datasets do not include either of these two additional
sources.
Uterine cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 11
Uterine cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. Axes and model definitions as in Figure 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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Errors in the flash dose itself are unlikely to explain the
results. Non-linearity and large values of ERR at 10 mSv
persist when the zero-dose data is deleted from the 0 – 20
mSv subcohort and likewise when ten intervals spanning
0 – 20 mSv are used to delete dose ranges from the data.
The DS02 dataset shows that there is virtually no misclas-
sification between the DS86 categories "below 5 mSv"
and "above 5 mSv". For the liver at latency 36.9 years, it
makes little difference whether dose is taken as a categor-
ical variable defined by the 5 mSv cutpoint in the data
stratification, or as a numerical value analysed with the
linear model.
DS02 and DS86 are in reasonable agreement above 5
mSv. If datacells with DS86 dose below 5 mSv are
excluded from the 0 – 20 mSv dose range, the two-phase
model is no longer a significant improvement on the lin-
ear model for the liver. However, very similar evidence of
non-linearity for the liver arises in the 5 mSv – 500 mSv
dose range where DS86 is a reasonable approximation to
DS02, and in the 0 – 500 mSv dose range considered by
Pierce and Preston [17].
Analysis of solid cancers using DS02 in the 0 – 20 mSv
dose range gives estimates of ERR comparable to those
derived from DS86.
These various arguments suggest that the results are
unlikely to be explained by errors in dosimetry of the flash
dose, although DS02 like DS86 is subject to some uncer-
tainty due to random errors in specifying individual loca-
All-solid cancer mortality in 0 – 20 mSv subcohort, LRT vs latency Figure 12
All-solid cancer mortality in 0 – 20 mSv subcohort, LRT vs latency. Axes and model definitions as in Figure 2.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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tion and shielding. Separately, induced radioactivity and
"black rain" represent additional doses not reported by
DS86 or DS02.
Induced radioactivity appears unlikely to fully explain the
results. According to the RERF website [6] "The closer to
the hypocentre, the higher was the dose [from induced
radioactivity]. Past investigations suggested that the max-
imum cumulative dose at the hypocentre from immedi-
ately after the bombing until today is 0.8 Gy in Hiroshima
and 0.3–0.4 Gy in Nagasaki. When the distance is 0.5 km
or 1.0 km from the hypocentre, the estimates are about 1/
10 and 1/100 of the value at the hypocentre, respectively."
The issue was examined in detail in the DS86 Final Report
Chapter 6 and an Appendix to this Chapter [8]. The cumu-
lative dose from induced radioactivity decreases exponen-
tially with distance from the hypocentre.
From the DS02 dataset, the minimum distance from the
hypocentre amongst cells with DS86 doses below 20 mSv
is 2.081 km while for cells with DS86 doses below 500
mSv it is 1.210 km. For the 5 – 500 mSv range the total
cumulative impact of induced radioactivity would be
below 8 mSv in Hiroshima and below 4 mSv in Nagasaki.
Consider the unlikely possibility that induced radioactiv-
ity adds 8 mSv to those cells which contain Hiroshima
liver cancer deaths, and 4 mSv to those cells which contain
Nagasaki liver cancer deaths, while leaving all other cells
unaffected. Under this extreme assumption, the two-
phase model at latency φ = 36.9 years has solutions with
ERR1 < 0 but the linear model gives LRTlin-con = 11.03 (1
df) and ERR1 = 0.029 (0.010, 0.054). Conversely, suppose
that induced radioactivity adds 8 mSv to those Hiroshima
cells which do not contain liver cancer deaths, and 4 mSv
to those Nagasaki cells which do not contain liver cancer
All-solid cancer mortality in 0 – 20 mSv subcohort, ERR vs latency Figure 13
All-solid cancer mortality in 0 – 20 mSv subcohort, ERR vs latency. Axes and model definitions as in Figure 3.Environmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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deaths, while leaving all other cells unaffected. Then the
linear model at latency φ = 36.9 years gives LRTlin-con =
4.63 (1 df) and ERR1 = 0.016 (0.001, 0.036), which is still
4.3 times higher than the LSS12 estimate. These two
extreme assumptions may perhaps provide limits on the
scope for induced radioactivity to affect the linear model
in the 5 – 500 mSv subcohort, where the corresponding
results without the addition of induced radioactivity are
LRTlin-con = 7.25 (1 df) and ERR1 = 0.021 (0.005, 0.044).
For the 0 – 20 mSv dose range the total cumulative impact
of induced radioactivity would be below 0.08 mSv in
Hiroshima and below 0.04 mSv in Nagasaki. Whatever
consequence this may have for the two-phase model, its
effect on the linear model is negligible.
"Black rain" fell primarily at some distance from the hypo-
centres. According to the RERF website, "Because of wind,
the rain mainly fell in northwestern Hiroshima (Koi-
Takasu area) and in eastern Nagasaki (Nishiyama area).
The maximum estimates of dose due to fallout are 0.01–
0.03 Gy in Hiroshima and 0.2–0.4 Gy in Nagasaki. The
corresponding doses at the hypocentres are believed to be
only about 1/10 of these values." According to Chapter 6
of the DS86 Final Report [8] the rainfall was concentrated
around 3000 m from the hypocentres in both cities. From
the DS02 dataset, the maximum distance from the hypo-
centre amongst cells with DS86 doses above 5 mSv is
2.683 km, somewhat closer to the hypocentres than the
main rainfall areas. Maximum doses from rainfall were
much lower in Hiroshima, though RERF do not give
enough detail to estimate an upper bound for the dose
from "black rain" in Hiroshima at distances below 2.683
km. However, if the Hiroshima data for the liver is ana-
lysed separately for the 5 – 500 mSv subcohort, the two-
phase model remains a significant improvement over the
linear model at latency φ = 36.9. LRT2p-lin = 5.718 (1 df)
Table 5: Comparison with extrapolations from LSS12a
Site gen LSS12 ERR1
b 2-p ERR1,φ
c φm
d trans ERR1,φ
e φm
f
Stomach M/F 0.0024 (0.001, 0.004) 0.46 (0.11, 0.94) 11.89 0.00 (-0.06, 0.16) 11.85
M 0.001 (-0.0005, 0.0028) 2.68 (-0.15, 32.45) 6.14 0.00 (-0.21, 0.17) 21.77
F 0.0047 (0.0022, 0.0077) 0.80 (0.15, 1.77) 13.67 0.43 (0.00, 0.96) 13.68
Liver M/F 0.0037 (0.0013, 0.0065) 1.43 (0.48, 2.95) 36.90 0.95 (0.28, 1.99) 36.90
M 0.0048 (0.0017, 0.0088) 1.72 (0.40, 4.25) 36.97 1.30 (0.28, 3.10) 36.97
F 0.0019 (-0.0011, 0.0062) 1.24 (0.06, 3.60) 36.90 1.09 (0.15, 2.78) 38.55
Lung M/F 0.0053 (0.0028, 0.0084) 0.88 (0.12, 3.36) 13.60 0.80 (0.19, 1.99) 13.60
M 0.0034 (0.0006, 0.0069) 0.78 (-0.11, 4.91) 13.55 0.74 (0.05, 2.40) 13.55
F 0.0089 (0.0041, 0.0151) 1.35 (0.07, 4.83) 21.91 1.04 (0.09, 3.28) 21.91
Colon M/F 0.0065 (0.0023, 0.0121) 0.05 (-0.53, 1.15) 20.28 0.07 (-0.49, 1.71) 43.98
M 0.0048 (-0.0002, 0.0127) 0.30 (-0.59, 3.16) 28.63 0.40 (-0.50, 2.72) 28.63
F 0.0081 (0.0022, 0.0077) 0.47 (-0.55, 2.96) 41.62 0.29 (-0.78, 2.26) 41.62
Uterus F 0.0024 (-0.0006, 0.0067) 0.47 (-0.32, 2.12) 26.91 0.000 (-0.23, 1.06) 26.91
Site gen LSS12 ERR0.025
b 2-p ERR0.025,φ
c φm
d trans ERR0.025,φ
d φm
f
Stomach M/F 0.00006 (0.000025, 0.0001) 0.39 (0.08, 0.86) 11.89 0.08 (-0.11, 0.23) 11.85
M 0.001 (-0.0005, 0.0028) 2.43 (-0.23, 31.08) 6.14 0.16 (-0.16, 0.47) 21.77
F 0.0047 (0.0022, 0.0077) 0.71 (0.05, 1.62) 13.67 0.30 (0.01, 0.76) 13.68
Liver M/F 0.000093 (0.000033, 0.00016) 1.10 (0.26, 2.37) 36.90 0.77 (0.18, 1.67) 36.90
M 0.00012 (0.000043, 0.00022) 1.30 (0.12, 3.50) 36.97 1.25 (0.25, 3.00) 36.97
F 0.000048 (-0.000028, 0.00016) 1.03 (0.04, 2.94) 36.90 0.43 (0.01, 1.46) 38.55
Lung M/F 0.00013 (0.00007, 0.00021) 0.86 (0.14, 3.34) 13.60 0.79 (0.20, 2.01) 13.60
M 0.000085 (0.000015, 0.00014) 0.96 (-0.05, 5.39) 13.55 0.92 (0.12, 2.92) 13.55
F 0.00022 (0.0001, 0.00038) 1.12 (0.08, 4.15) 21.91 0.91 (0.10, 2.87) 21.91
Colon M/F 0.00017 (0.00006, 0.0003) 0.25 (-0.44, 1.46) 20.28 0.58 (-0.25, 1.85) 43.98
M 0.00012 (-0.000005, 0.00032) 0.65 (-0.45, 4.34) 28.63 0.72 (-0.30, 3.72) 28.63
F 0.0002 (0.000055, 0.00019) 0.94 (-0.21, 3.17) 41.62 0.85 (-0.15, 2.56) 41.62
Uterus F 0.00006 (-0.000015, 0.00017) 0.66 (-0.10, 2.44) 26.91 0.25 (-0.09, 1.13) 26.91
a Life Span Study Report 12 [4]
b from LSS12 Tables AII, AIII and AIV, scaled by the linear assumption ERR1 = ERR per 10 mSv = 0.01(ERR per Sv) and ERR0.025 = 0.00025(ERR per 
Sv)
c Two-phase model fitted to 0 – 20 mSv subcohort at optimal latency (see also Table 3 for M/F results)
d Optimal latency for Two-phase model on 0 – 20 mSv subcohort
e Transient model at fitted to 0 – 20 mSv subcohort at optimal latency (see also Table 2 for M/F results)
f Optimal latency for Transient model on 0 – 20 mSv subcohortEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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and ERR1 = 0.674 (-0.06, 1.92) while for the linear model
LRTlin-con = 7.946 and ERR1 = 0.027 (0.007, 0.055).
Compounding the uncertainty over doses from "black
rain", individuals may have travelled into a rainfall area
even if they were outside it when the bombs exploded.
RERF's estimates refer to external doses, omitting any
inhaled or ingested radiation. In any case the conclusions
are provisional until a dataset for specific solid cancers
showing DS02 flash doses, induced radioactivity and
"black rain" becomes available. Potential confounding by
other risk factors cannot be excluded. The neutron RBE of
10 used here, as in LSS12 and elsewhere, may be inappro-
priate. Despite all these reservations, which also affect the
LSS studies, it is striking that both the 0 – 20 mSv and 5 –
500 mSv subcohorts show non-linear dose response for
the liver and the two-phase model gives comparable esti-
mates from both subcohorts for Excess Relative Risk at 10
mSv with latency 36.9 years. "Black rain" and induced
radioactivity have quite different impacts within these two
subcohorts.
I do not know whether these results and the optimal
latencies are specific to the A-bomb cohort. In their study
of gamma radiation and mortality in the Oak Ridge work-
force, Frome et al. [18] find a 'Low-dose β' value of 2.9
with LRT = 3.12 (p = 0.08) for the combined digestive cat-
egory using a multiplicative model (without latency) with
dose restricted to 0 – 640 mSv. Since their unit dose is 1
Sv this corresponds to ERR1 = 0.029.
Non-linear models are applied here without assuming
any cellular mechanism, and their success in fitting the
cohort data does not prove that any particular cell mech-
anism operated there. However, the two-phase model
adapts and simplifies a model derived by Brenner et al.
[19] to explain the 'oncogenic transformation frequency'
of cells exposed to broad beam irradiation by α particles:
TF = νq<N> + σ [1-e(-k<N>)] [e(-q<N>)]
TF is the number of transformed cells per surviving cell
(Excess Relative Risk of transformation); ν is the transfor-
mation frequency for cells struck directly by exactly one α
particle, q the surviving fraction of cells struck directly by
exactly one α particle, <N> the mean number of α parti-
cles striking each cell in the broad beam irradiation (a
dose variable), k the number of cells receiving the
bystander signal emitted from a cell struck directly by one
or more α particles, and σ the (presumed) hypersensitive
fraction of bystander cells which are transformed on
receipt of any bystander signal. Note that the first term in
the TF expression refers to direct effects, whilst the second
term refers to bystander effects. As a function of <N>, TF is
approximately linear with slope ν q + σ k at very low doses
and approximately linear with slope ν q at higher doses.
The two-phase model is asymptotically linear with slope
σ + β at very low doses and asymptotically linear with
slope β at higher doses. It generates curves of the same
qualitative shape as the TF cell model.
In the cell model, the ratio of asymptotic slopes is R =
1+(σ k/ν q). From targetted microbeam experiments on
C3H 10T1/2 mouse fibroblast cells, Brenner et al. estimate
ν = 1.3 × 10-4, σ = 6.4 × 10-4, and q = 0.8. Thus R ~ 1 + 6.2
k. In a subsequent paper Brenner and Sachs [20] suggest
that k ~ 50 (so R ~ 311) for the human lung, from model-
ling dose-rate effects in (male) uranium miners exposed
to radon.
Table 6: Two-phase and linear models fittted to subsets of the liver dataa
iR i
b p-y in Si
c Casesd LRTe ERR1
f
1 0 – 0.01552 1522195.93 441 22.00 1.67
2 0.015521 – 0.019389 1520822.41 459 18.94 1.28
3 0.19396 – 0.022682 1521452.84 499 27.01 1.49
4 0.022687 – 0.025616 1521872.88 500 30.31 1.57
5 0.025619 – 0.30046 1521932.58 510 28.61 1.42
6 0.030066 – 0.037161 1522215.36 494 26.14 1.37
7 0.037211 – 0.87187 1521303.24 483 26.31 1.50
8 0.87209 – 0.97152 1521034.77 492 30.44 1.36
9 0.97154 – 1.0107 1521559.95 507 28.56 1.74
10 1.0108 – 2.000 1519135.79 475 26.42 1.21
a The two-phase and linear models are fitted to subsets of the 0 – 20 mSv liver data with latency φ = 36.90 years (optimal for the two-phase model 
on the 0 – 20 mSv data, see Table 3)
b Ri is the excluded dose range (in 10 mSv units). Si consists of those cells in the 0 – 20 mSv subcohort whose weighted adjusted colon dose does 
not fall in Ri
c Person-years in Si
d Cases (liver cancer deaths) in Si
e LRT = LRT2p-lin for comparing the two-phase model with the linear model when fitted to Si with latency φ = 36.90 years
f ERR1 is the estimated Excess Relative Risk at 10 mSv when the two-phase model with latency φ = 36.90 years is fitted to SiEnvironmental Health 2007, 6:1 http://www.ehjournal.net/content/6/1/1
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In the two-phase model, the ratio of asymptotic slopes is
R = 1 + σ/β. For the male lung, with optimal latency 13.55
years, R = 202.22. For the lung, the two-phase model is
not significant against the transient and the confidence
region for R is infinite and includes negative values. But
for the stomach (M/F) R = 262.62 with 95% CI (102.41,
975.09), and for the liver (M/F) R  = 204.11 (58.29,
792.85). Thus the low dose A-bomb data is compatible
with a bystander model using roughly comparable values
of k, the number of cells receiving the bystander signal.
The flash dose comprised gamma and neutron doses. An
appropriate cell model for bystander effects following
gamma radiation may differ from that developed for α
particles, where the impact of a single track on one cell is
quite large. However fission neutrons, like α particles, are
high LET (linear energy transfer) and might elicit a similar
bystander signal. Induction of genomic instability in unir-
radiated bystander cells has been demonstrated for neu-
tron irradiation in mice [21].
Non-linear dose response curves can also arise from a
hypersensitive population subset [22]. Sharp et al. [23]
analysed primary liver cancer mortality in relation to Hep-
atitis B and C in Japanese A-bomb survivors and found a
very strong supermultiplicative interaction between HVC
and radiation dose, but only for the high and medium
dose ranges. For doses below 18 mSv, there was no signif-
icant interaction. However, Sharp et al. did not include
latency and truncated all liver doses below 3 mSv. I could
not analyse primary liver cancer because the data in
r12canc.dat shows all liver cancers. Persistent inflamma-
tion including chronic liver disease has been detected in
Japanese survivors 40 years after the bombing and corre-
lated with radiation dose [24].
Conclusion
All the models considered here show unexpectedly large
and significant results in the 0 – 20 mSv dose range when
a lagged colon dose is taken as the main predictor. Non-
linear models allowing for asymptotic effects as dose
approaches 0 improve the fit and give a much higher slope
for the dose response curve near 0 than at higher doses.
Whether or not analyses of this cohort can be transferred
internationally, the results here raise questions in Japan.
In any case, significant results for doses below 20 mSv are
directly relevant to the current ICRP recommendations
limiting annual occupational exposure to 20 mSv (whole
body dose). Analysis of the 0 – 20 mSv dose range gives
responses several orders of magnitude above extrapola-
tions from LSS12 (and other Life Span Studies).
Low dose effects which depend on latency or are detected
by non-linear models can still cause significant risks.
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